Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-2: clinical applications.

Michael B Atkins1

  • 1Cutaneous Oncology & Biologic Therapy Programs, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.

Seminars in Oncology
|June 18, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.

Journal for immunotherapy of cancer·2026
Same author

Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma.

Journal for immunotherapy of cancer·2026
Same author

Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy.

Cancer medicine·2026
Same author

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

CA: a cancer journal for clinicians·2025
Same author

Differentiated Thyroid Cancer Is Associated With Sex-specific Immune Response.

Journal of the Endocrine Society·2025
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Interleukin-2 (IL-2) shows promise for cancers like melanoma and leukemia. High-dose IL-2 offers benefits but has toxicities, while low-dose IL-2 has shown limited efficacy, necessitating further research for improved cancer immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Interleukin-2 (IL-2) is an immunotherapeutic agent investigated for metastatic melanoma, acute myelogenous leukemia, and metastatic renal cell carcinoma.
  • High-dose IL-2 regimens demonstrate clinical benefits for melanoma and renal cell carcinoma but are limited by dose-limiting toxicities.
  • Low-dose IL-2 therapy has yielded suboptimal response rates in melanoma and raises concerns about response quality in renal cell carcinoma compared to high-dose IL-2.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of different Interleukin-2 (IL-2) regimens in treating specific cancers.
  • To assess the clinical utility of low-dose IL-2 and biochemotherapy in managing metastatic melanoma and renal cell carcinoma.
  • To explore potential improvements in IL-2-based cancer treatment strategies.

Related Experiment Videos

Main Methods:

  • Review of clinical data on high-dose and low-dose Interleukin-2 (IL-2) therapy.
  • Analysis of response rates and survival data for IL-2 in melanoma, leukemia, and renal cell carcinoma.
  • Evaluation of outcomes associated with biochemotherapy (IL-2 combined with chemotherapy).

Main Results:

  • High-dose IL-2 shows clinical benefit but significant toxicities in melanoma and renal cell carcinoma.
  • Low-dose IL-2 demonstrates disappointing response rates in melanoma and variable response quality in renal cell carcinoma.
  • Biochemotherapy yields high overall response rates in melanoma but has not yet proven improved survival.

Conclusions:

  • The clinical application of Interleukin-2 (IL-2) in cancer immunotherapy is constrained by dose-limiting toxicities and variable efficacy.
  • Further research is needed to optimize IL-2-based regimens, potentially through combination with novel agents, to enhance tumor response and patient survival.
  • The optimal use of IL-2 in treating metastatic melanoma, acute myelogenous leukemia, and metastatic renal cell carcinoma requires further investigation and refinement.